Contemporary Implantable Cardioverter-Defibrillator Benefit
JACC: Clinical Electrophysiology · 2025-10 · 11 (10) · 2238-2247
DOI: 10.1016/j.jacep.2025.06.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2025-10. Verfasst von Anne B Curtis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA. Electronic address: abcurtis@buffalo.edu. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Death, Sudden, Cardiac, Time-to-Treatment. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Implantable cardioverter-defibrillators (ICDs) reduce mortality in patients at risk of sudden cardiac death. Recent improvements in heart failure care may impact the rate of ICD therapy received by patients. Thus, an updated examination of ICD benefit is needed. OBJECTIVES: This study sought to assess time to first therapy in contemporary ICD patients and infer the proportion of appropriate therapies based on an adjudicated subset of randomly selected episodes. METHODS: A query of the Medtronic CareLink de-identified database from 2013 to 2024 was performed. First-time Medtronic ICD recipients implanted with a single- or dual-chamber ICD were included. Cumulative incidence function curves were generated for time to first shock therapy, antitachycardia pacing (ATP) therapy, and any therapy (shock or ATP). Three adjudicators analyzed 595 randomly selected episodes manually to assess appropriateness of therapy. Results from adjudication were then used to model therapy appropriateness of the rest of the episodes in the database. RESULTS: There were 237,627 patients (71.8% male) included in the analysis. The cumulative incidence of first appropriate shock, ATP, or any appropriate therapy was 33%, 42%, and 48% at 10 years, respectively. Secondary prevention ICD-indicated patients had a higher 10-year cumulative incidence of first appropriate shock (41% vs 32%), ATP (51% vs 40%), or any appropriate therapy (58% vs 45%) than primary prevention patients. CONCLUSIONS: Nearly half of contemporary patients receive appropriate ICD therapy by 10 years postimplantation. These data indicate continued benefit of ICD therapy despite modern refinements to device management and medical and interventional cardiac care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA. Electronic address: abcurtis@buffalo.edu.
- Division of Cardiology, Istituto Cardiocentro Ticino, Ente Ospedaliero Cantonale, Lugano, Switzerland.
- Electrophysiology, Valley Health System, Ridgewood, New Jersey, USA.
- Saint Thomas Research Institute, Nashville, Tennessee, USA.
- Medtronic Inc, Mounds View, Minnesota, USA.
- Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Zitieren
APA
Curtis, A. B., Auricchio, A., Mittal, S., Pickett, R. A., Holmes, T. R., Jacobsen, L. D., Lande, J. D., & Wilkoff, B. L. (2025). Contemporary Implantable Cardioverter-Defibrillator Benefit. JACC: Clinical Electrophysiology, 11(10), 2238-2247. https://doi.org/10.1016/j.jacep.2025.06.028
Vancouver
Curtis AB, Auricchio A, Mittal S, Pickett RA, Holmes TR, Jacobsen LD, et al. Contemporary Implantable Cardioverter-Defibrillator Benefit. JACC: Clinical Electrophysiology. 2025;11(10):2238-2247. doi:10.1016/j.jacep.2025.06.028
BibTeX
@article{Curtis2025,
author = {Curtis, Anne B and Auricchio, Angelo and Mittal, Suneet and Pickett, Robert A and Holmes, Thomas R and Jacobsen, Luke D and Lande, Jeff D and Wilkoff, Bruce L},
title = {Contemporary Implantable Cardioverter-Defibrillator Benefit},
journal = {JACC: Clinical Electrophysiology},
year = {2025},
volume = {11},
number = {10},
pages = {2238--2247},
doi = {10.1016/j.jacep.2025.06.028}
}
EUVIMED